VANCOUVER, BC / ACCESSWIRE / November 30, 2016 / CVR Medical Corp. CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) announces partnership with Dr. David J. Whellan and Thomas Jefferson University in Philadelphia for the design and conduction of clinical trials for its “Carotid Stenotic Scan (CSS)” device.
Dr. Whellan is the Principal Investigator of Jefferson Regional Clinical Center for the NIH HF Network, one of nine centers across the United States selected to participate in a series of novel heart failure clinical trials. Recognized as preeminent in the cardiovascular healthcare field, his extensive clinical research has produced over 175 peer-reviewed publications on cardiovascular disease, including cardiomyopathy, aspirin use and coronary bypass surgery. His partnership with CVR Global signals a much-anticipated step toward providing evidence regarding the CSS for diagnostic accuracy. With the unique capabilities present at Thomas Jefferson University, the study will compare CSS with existing arterial diagnostic tools across a wide range of potential subjects. CVR executive management looks forward to working with Dr. Whellan and the institution, and expresses great confidence that the upcoming trials will be a thorough and successful vetting that will position the CSS strongly ahead of its market launch.
Commenting on this partnership, Dr. Whellan states, “We have built a model here at Thomas Jefferson University to engage with companies like CVR Global in the evaluation of novel diagnostics and treatments for a wide variety of patients. What drew us to this project is that it’s a technology that fits within our emphasis on innovation. We want to be a leading organization for the evaluation of novel therapies and diagnostic technologies.”
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.